世界の抗悪性腫瘍剤の主要動向と2027年までの機会

Global Antineoplastic Agents Key Trends and Opportunities to 2027

新たな抗腫瘍ターゲットとそれに対応する新たな抗腫瘍剤・手段として、プロテインチロシンキナーゼ阻害剤、ファルネシルトランスフェラーゼ(FTase)阻害剤、MAPKシグナル伝達経路阻害剤、細胞周期制御剤などの細胞... もっと見る

出版社	出版年月	電子版価格	言語
QYResearch QYリサーチ	2021年11月26日	US$6,600 シングルユーザライセンスライセンス・価格情報注文方法はこちら	英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

新たな抗腫瘍ターゲットとそれに対応する新たな抗腫瘍剤・手段として、プロテインチロシンキナーゼ阻害剤、ファルネシルトランスフェラーゼ(FTase)阻害剤、MAPKシグナル伝達経路阻害剤、細胞周期制御剤などの細胞シグナル伝達分子を標的とするものが挙げられる。新生血管を標的とするもの：新生血管阻害剤;がん細胞の剥離、接着、基底膜の劣化を抑えるもの：抗転移剤;テロメラーゼを標的とするもの：テロメラーゼ阻害剤;腫瘍細胞に対する薬剤耐性を高めるもの：薬剤耐性回復剤;悪性細胞の成熟分化を促進するもの：分化誘導剤;がん細胞を特異的に殺傷するもの :(抗体または毒素）指向性治療;放射線治療や化学療法の効果を高める：腫瘍治療増感剤;集団的な免疫機能を高めるまたは調節する：生物学的反応調節剤;癌遺伝子や腫瘍抑制遺伝子に対して：遺伝子治療-野生型腫瘍抑制遺伝子、自殺遺伝子、抗薬剤耐性遺伝子、アンチセンスオリゴヌクレオチドの導入、腫瘍遺伝子工学腫瘍菌。

市場分析とインサイト抗悪性腫瘍剤の世界市場
2020年の抗悪性腫瘍剤の世界市場規模はXX百万米ドルで、2021-2027年の間にXX％のCAGRで、2027年末にはXX百万米ドルに達すると予想されています。

抗悪性腫瘍剤の世界市場の範囲と市場規模
抗悪性腫瘍剤市場は、企業別、地域（国）別、タイプ別、用途別に分類されています。世界のAntineoplastic Agents市場に参加するプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年までの市場規模と予測に焦点を当てています。
タイプ別では、抗悪性腫瘍剤市場は、化学療法、標的療法、免疫療法、ホルモン療法（生物学的療法）、その他などに分類されます。
用途別では、抗悪性腫瘍剤市場は、植物薬、ホルモン、白金化合物、薬剤耐性の代謝、低分子の標的化、がん治療薬、抗生物質、アルキル化剤、化学放射線治療保護剤などに分類されています。

地域・国別分析
当レポートでは、米国、カナダ、ドイツ、フランス、英国、イタリア、ロシア、中国、日本、韓国、台湾、インド、オーストラリア、インドネシア、タイ、マレーシア、フィリピン、ベトナム、メキシコ、ブラジル、アルゼンチン、サウジアラビア、アラブ首長国連邦、トルコなど、地域別・国別の抗悪性腫瘍剤市場を網羅的に評価しています。
本レポートでは、2016-2027年の期間において、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカの国（地域）別、タイプ別、アプリケーション別の市場規模、およびプレイヤー別の市場規模を掲載しています。

競合環境と抗悪性腫瘍剤市場シェア分析
Antineoplastic Agents市場の競合状況では、ベンダーによる詳細やデータ情報を提供しています。本レポートでは、2016年から2021年までの期間、プレイヤーによる収益に関する包括的な分析と正確な統計を提供しています。また、2016年から2021年の期間におけるプレイヤー別の収益（世界および地域レベル）について、信頼性の高い統計に支えられた詳細な分析を提供しています。含まれる詳細は、会社概要、主要事業、会社の総収入とAntineoplastic Agents事業で得た収入、Antineoplastic Agents市場への参入日、Antineoplastic Agentsの製品紹介、最近の開発状況などです。
主要ベンダーとしては、BMS、MSD、ジョンソン・エンド・ジョンソン、ファイザー、アストラゼネカ、ノバルティス、サノフィ、セルジーン、ロシュ、リリー、バイエル、アブラキシス、ギリアド、Wto-Day Order Pharmaceutical、Sinopharm、Shandong Lvye Pharmaceutical、CTTQ、Jiangsu Hengrui Pharmaceutical、Qilu Pharmaceutical、Baekdu Mountain Pharmaceuticalなどが挙げられます。

ページTOPに戻る

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antineoplastic Agents Market Size by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Hormonal Therapy (Biologic Therapy)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Antineoplastic Agents Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Plant Medicine
1.3.3 Hormone
1.3.4 Platinum Compounds
1.3.5 Metabolism Of Drug Resistance
1.3.6 Targeting Small Molecules
1.3.7 Drugs For Cancer
1.3.8 Antibiotic
1.3.9 Alkylating Agent
1.3.10 Chemoradiotherapy Protectant
1.3.11 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trend
2.1 Global Antineoplastic Agents Market Perspective (2016-2027)
2.2 Global Antineoplastic Agents Growth Trends by Regions
2.2.1 Antineoplastic Agents Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antineoplastic Agents Historic Market Size by Regions (2016-2021)
2.2.3 Antineoplastic Agents Forecasted Market Size by Regions (2022-2027)
2.3 Industry Trends and Growth Strategy
2.3.1 Antineoplastic Agents Industry Trends
2.3.2 Antineoplastic Agents Market Drivers
2.3.3 Antineoplastic Agents Market Challenges
2.3.4 Antineoplastic Agents Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antineoplastic Agents Players by Market Size
3.1.1 Players Covered: Ranking by Antineoplastic Agents Revenue
3.1.2 Global Top Antineoplastic Agents Players by Revenue (2016-2021)
3.1.3 Global Antineoplastic Agents Revenue Market Share by Players (2016-2021)
3.1.4 Global Antineoplastic Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Antineoplastic Agents Market Concentration Ratio
3.2.1 Global Antineoplastic Agents Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 5 and Top 10 Players by Antineoplastic Agents Revenue in 2020
3.3 Antineoplastic Agents Key Players Head office and Area Served
3.4 Key Players Antineoplastic Agents Product Solution and Service
3.5 Date of Enter into Antineoplastic Agents Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Global Antineoplastic Agents Breakdown Data by Type (2016-2027)
4.1 Global Antineoplastic Agents Historic Market Size by Type (2016-2021)
4.2 Global Antineoplastic Agents Forecasted Market Size by Type (2022-2027)

5 Global Antineoplastic Agents Breakdown Data by Application (2016-2027)
5.1 Global Antineoplastic Agents Historic Market Size by Application (2016-2021)
5.2 Antineoplastic Agents Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antineoplastic Agents Market Size (2016-2027)
6.2 Key Antineoplastic Agents Players Market Share in North America (2020-2021)
6.3 North America Antineoplastic Agents Market Size by Country
6.3.1 North America Antineoplastic Agents Market Size by Country (2016-2021)
6.3.2 North America Antineoplastic Agents Market Size Forecast by Country (2022-2027)
6.4 U.S. Market Size Analysis
6.4.1 U.S. Antineoplastic Agents Market Size (2016-2027)
6.4.2 U.S. Antineoplastic Agents Market Size by Type (2016-2027)
6.4.3 U.S. Antineoplastic Agents Market Size by Application (2016-2027)
6.5 Canada Market Size Analysis
6.5.1 Canada Antineoplastic Agents Market Size (2016-2027)
6.5.2 Canada Antineoplastic Agents Market Size by Type (2016-2027)
6.5.3 Canada Antineoplastic Agents Market Size by Application (2016-2027)

7 Europe
7.1 Europe Antineoplastic Agents Market Size (2016-2027)
7.2 Key Antineoplastic Agents Players Market Share in Europe (2020-2021)
7.3 Europe Antineoplastic Agents Market Size by Country
7.3.1 Europe Antineoplastic Agents Market Size by Country (2016-2021)
7.3.2 Europe Antineoplastic Agents Market Size Forecast by Country (2022-2027)
7.4 Germany Market Size Analysis
7.4.1 Germany Antineoplastic Agents Market Size (2016-2027)
7.4.2 Germany Antineoplastic Agents Market Size by Type (2016-2027)
7.4.3 Germany Antineoplastic Agents Market Size by Application (2016-2027)
7.5 France Market Size Analysis
7.5.1 France Antineoplastic Agents Market Size (2016-2027)
7.5.2 France Antineoplastic Agents Market Size by Type (2016-2027)
7.5.3 France Antineoplastic Agents Market Size by Application (2016-2027)
7.6 U.K. Market Size Analysis
7.6.1 U.K. Antineoplastic Agents Market Size (2016-2027)
7.6.2 U.K. Antineoplastic Agents Market Size by Type (2016-2027)
7.6.3 U.K. Antineoplastic Agents Market Size by Application (2016-2027)
7.7 Italy Market Size Analysis
7.7.1 Italy Antineoplastic Agents Market Size (2016-2027)
7.7.2 Italy Antineoplastic Agents Market Size by Type (2016-2027)
7.7.3 Italy Antineoplastic Agents Market Size by Application (2016-2027)
7.8 Russia Market Size Analysis
7.8.1 Russia Antineoplastic Agents Market Size (2016-2027)
7.8.2 Russia Antineoplastic Agents Market Size by Type (2016-2027)
7.8.3 Russia Antineoplastic Agents Market Size by Application (2016-2027)

8 Asia-Pacific
8.1 Asia-Pacific Antineoplastic Agents Market Size (2016-2027)
8.2 Key Antineoplastic Agents Players Market Share in Asia-Pacific (2020-2021)
8.3 Asia-Pacific Antineoplastic Agents Market Size by Region
8.3.1 Asia-Pacific Antineoplastic Agents Market Size by Region (2016-2021)
8.3.2 Asia-Pacific Antineoplastic Agents Market Size Forecast by Region (2022-2027)
8.4 China Market Size Analysis
8.4.1 China Antineoplastic Agents Market Size (2016-2027)
8.4.2 China Antineoplastic Agents Market Size by Type (2016-2027)
8.4.3 China Antineoplastic Agents Market Size by Application (2016-2027)
8.5 Japan Market Size Analysis
8.5.1 Japan Antineoplastic Agents Market Size (2016-2027)
8.5.2 Japan Antineoplastic Agents Market Size by Type (2016-2027)
8.5.3 Japan Antineoplastic Agents Market Size by Application (2016-2027)
8.6 South Korea Market Size Analysis
8.6.1 South Korea Antineoplastic Agents Market Size (2016-2027)
8.6.2 South Korea Antineoplastic Agents Market Size by Type (2016-2027)
8.6.3 South Korea Antineoplastic Agents Market Size by Application (2016-2027)
8.7 India Market Size Analysis
8.7.1 India Antineoplastic Agents Market Size (2016-2027)
8.7.2 India Antineoplastic Agents Market Size by Type (2016-2027)
8.7.3 India Antineoplastic Agents Market Size by Application (2016-2027)
8.8 Australia Market Size Analysis
8.8.1 Australia Antineoplastic Agents Market Size (2016-2027)
8.8.2 Australia Antineoplastic Agents Market Size by Type (2016-2027)
8.8.3 Australia Antineoplastic Agents Market Size by Application (2016-2027)
8.9 Taiwan Market Size Analysis
8.9.1 Taiwan Antineoplastic Agents Market Size (2016-2027)
8.9.2 Taiwan Antineoplastic Agents Market Size by Type (2016-2027)
8.9.3 Taiwan Antineoplastic Agents Market Size by Application (2016-2027)
8.10 Indonesia Market Size Analysis
8.10.1 Indonesia Antineoplastic Agents Market Size (2016-2027)
8.10.2 Indonesia Antineoplastic Agents Market Size by Type (2016-2027)
8.10.3 Indonesia Antineoplastic Agents Market Size by Application (2016-2027)
8.11 Thailand Market Size Analysis
8.11.1 Thailand Antineoplastic Agents Market Size (2016-2027)
8.11.2 Thailand Antineoplastic Agents Market Size by Type (2016-2027)
8.11.3 Thailand Antineoplastic Agents Market Size by Application (2016-2027)
8.12 Malaysia Market Size Analysis
8.12.1 Malaysia Antineoplastic Agents Market Size (2016-2027)
8.12.2 Malaysia Antineoplastic Agents Market Size by Type (2016-2027)
8.12.3 Malaysia Antineoplastic Agents Market Size by Application (2016-2027)
8.13 Philippines Market Size Analysis
8.13.1 Philippines Antineoplastic Agents Market Size (2016-2027)
8.13.2 Philippines Antineoplastic Agents Market Size by Type (2016-2027)
8.13.3 Philippines Antineoplastic Agents Market Size by Application (2016-2027)
8.14 Vietnam Market Size Analysis
8.14.1 Vietnam Antineoplastic Agents Market Size (2016-2027)
8.14.2 Vietnam Antineoplastic Agents Market Size by Type (2016-2027)
8.14.3 Vietnam Antineoplastic Agents Market Size by Application (2016-2027)

9 Latin America
9.1 Latin America Antineoplastic Agents Market Size (2016-2027)
9.2 Key Antineoplastic Agents Players Market Share in Latin America (2020-2021)
9.3 Latin America Antineoplastic Agents Market Size by Country
9.3.1 Latin America Antineoplastic Agents Market Size by Country (2016-2021)
9.3.2 Latin America Antineoplastic Agents Market Size Forecast by Country (2022-2027)
9.4 Mexico Market Size Analysis
9.4.1 Mexico Antineoplastic Agents Market Size (2016-2027)
9.4.2 Mexico Antineoplastic Agents Market Size by Type (2016-2027)
9.4.3 Mexico Antineoplastic Agents Market Size by Application (2016-2027)
9.5 Brazil Market Size Analysis
9.5.1 Brazil Antineoplastic Agents Market Size (2016-2027)
9.5.2 Brazil Antineoplastic Agents Market Size by Type (2016-2027)
9.5.3 Brazil Antineoplastic Agents Market Size by Application (2016-2027)
9.6 Argentina Market Size Analysis
9.6.1 Argentina Antineoplastic Agents Market Size (2016-2027)
9.6.2 Argentina Antineoplastic Agents Market Size by Type (2016-2027)
9.6.3 Argentina Antineoplastic Agents Market Size by Application (2016-2027)

10 Middle East & Africa
10.1 Middle East & Africa Antineoplastic Agents Market Size (2016-2027)
10.2 Key Antineoplastic Agents Players Market Share in Middle East & Africa (2020-2021)
10.3 Middle East & Africa Antineoplastic Agents Market Size by Country
10.3.1 Middle East & Africa Antineoplastic Agents Market Size by Country (2016-2021)
10.3.2 Middle East & Africa Antineoplastic Agents Market Size Forecast by Country (2022-2027)
10.4 Turkey Market Size Analysis
10.4.1 Turkey Antineoplastic Agents Market Size (2016-2027)
10.4.2 Turkey Antineoplastic Agents Market Size by Type (2016-2027)
10.4.3 Turkey Antineoplastic Agents Market Size by Application (2016-2027)
10.5 Saudi Arabia Market Size Analysis
10.5.1 Saudi Arabia Antineoplastic Agents Market Size (2016-2027)
10.5.2 Saudi Arabia Antineoplastic Agents Market Size by Type (2016-2027)
10.5.3 Saudi Arabia Antineoplastic Agents Market Size by Application (2016-2027)
10.6 UAE Market Size Analysis
10.6.1 UAE Antineoplastic Agents Market Size (2016-2027)
10.6.2 UAE Antineoplastic Agents Market Size by Type (2016-2027)
10.6.3 UAE Antineoplastic Agents Market Size by Application (2016-2027)

11 Key Players Profiles
11.1 BMS
11.1.1 BMS Company Details
11.1.2 BMS Business Overview and Its Total Revenue
11.1.3 BMS Antineoplastic Agents Introduction
11.1.4 BMS Revenue in Antineoplastic Agents Business (2016-2021)
11.1.5 BMS Recent Development
11.2 MSD
11.2.1 MSD Company Details
11.2.2 MSD Business Overview and Its Total Revenue
11.2.3 MSD Antineoplastic Agents Introduction
11.2.4 MSD Revenue in Antineoplastic Agents Business (2016-2021)
11.2.5 MSD Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview and Its Total Revenue
11.3.3 Johnson & Johnson Antineoplastic Agents Introduction
11.3.4 Johnson & Johnson Revenue in Antineoplastic Agents Business (2016-2021)
11.3.5 Johnson & Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview and Its Total Revenue
11.4.3 Pfizer Antineoplastic Agents Introduction
11.4.4 Pfizer Revenue in Antineoplastic Agents Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview and Its Total Revenue
11.5.3 AstraZeneca Antineoplastic Agents Introduction
11.5.4 AstraZeneca Revenue in Antineoplastic Agents Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview and Its Total Revenue
11.6.3 Novartis Antineoplastic Agents Introduction
11.6.4 Novartis Revenue in Antineoplastic Agents Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview and Its Total Revenue
11.7.3 Sanofi Antineoplastic Agents Introduction
11.7.4 Sanofi Revenue in Antineoplastic Agents Business (2016-2021)
11.7.5 Sanofi Recent Development
11.8 Celgene
11.8.1 Celgene Company Details
11.8.2 Celgene Business Overview and Its Total Revenue
11.8.3 Celgene Antineoplastic Agents Introduction
11.8.4 Celgene Revenue in Antineoplastic Agents Business (2016-2021)
11.8.5 Celgene Recent Development
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview and Its Total Revenue
11.9.3 Roche Antineoplastic Agents Introduction
11.9.4 Roche Revenue in Antineoplastic Agents Business (2016-2021)
11.9.5 Roche Recent Development
11.10 Lilly
11.10.1 Lilly Company Details
11.10.2 Lilly Business Overview and Its Total Revenue
11.10.3 Lilly Antineoplastic Agents Introduction
11.10.4 Lilly Revenue in Antineoplastic Agents Business (2016-2021)
11.10.5 Lilly Recent Development
11.11 Bayer
11.11.1 Bayer Company Details
11.11.2 Bayer Business Overview and Its Total Revenue
11.11.3 Bayer Antineoplastic Agents Introduction
11.11.4 Bayer Revenue in Antineoplastic Agents Business (2016-2021)
11.11.5 Bayer Recent Development
11.12 Abraxis
11.12.1 Abraxis Company Details
11.12.2 Abraxis Business Overview and Its Total Revenue
11.12.3 Abraxis Antineoplastic Agents Introduction
11.12.4 Abraxis Revenue in Antineoplastic Agents Business (2016-2021)
11.12.5 Abraxis Recent Development
11.13 Gilead
11.13.1 Gilead Company Details
11.13.2 Gilead Business Overview and Its Total Revenue
11.13.3 Gilead Antineoplastic Agents Introduction
11.13.4 Gilead Revenue in Antineoplastic Agents Business (2016-2021)
11.13.5 Gilead Recent Development
11.14 Wto-Day Order Pharmaceutical
11.14.1 Wto-Day Order Pharmaceutical Company Details
11.14.2 Wto-Day Order Pharmaceutical Business Overview and Its Total Revenue
11.14.3 Wto-Day Order Pharmaceutical Antineoplastic Agents Introduction
11.14.4 Wto-Day Order Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.14.5 Wto-Day Order Pharmaceutical Recent Development
11.15 Sinopharm
11.15.1 Sinopharm Company Details
11.15.2 Sinopharm Business Overview and Its Total Revenue
11.15.3 Sinopharm Antineoplastic Agents Introduction
11.15.4 Sinopharm Revenue in Antineoplastic Agents Business (2016-2021)
11.15.5 Sinopharm Recent Development
11.16 Shandong Lvye Pharmaceutical
11.16.1 Shandong Lvye Pharmaceutical Company Details
11.16.2 Shandong Lvye Pharmaceutical Business Overview and Its Total Revenue
11.16.3 Shandong Lvye Pharmaceutical Antineoplastic Agents Introduction
11.16.4 Shandong Lvye Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.16.5 Shandong Lvye Pharmaceutical Recent Development
11.17 CTTQ
11.17.1 CTTQ Company Details
11.17.2 CTTQ Business Overview and Its Total Revenue
11.17.3 CTTQ Antineoplastic Agents Introduction
11.17.4 CTTQ Revenue in Antineoplastic Agents Business (2016-2021)
11.17.5 CTTQ Recent Development
11.18 Jiangsu Hengrui Pharmaceutical
11.18.1 Jiangsu Hengrui Pharmaceutical Company Details
11.18.2 Jiangsu Hengrui Pharmaceutical Business Overview and Its Total Revenue
11.18.3 Jiangsu Hengrui Pharmaceutical Antineoplastic Agents Introduction
11.18.4 Jiangsu Hengrui Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.18.5 Jiangsu Hengrui Pharmaceutical Recent Development
11.19 Qilu Pharmaceutical
11.19.1 Qilu Pharmaceutical Company Details
11.19.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
11.19.3 Qilu Pharmaceutical Antineoplastic Agents Introduction
11.19.4 Qilu Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.19.5 Qilu Pharmaceutical Recent Development
11.20 Baekdu Mountain Pharmaceutical
11.20.1 Baekdu Mountain Pharmaceutical Company Details
11.20.2 Baekdu Mountain Pharmaceutical Business Overview and Its Total Revenue
11.20.3 Baekdu Mountain Pharmaceutical Antineoplastic Agents Introduction
11.20.4 Baekdu Mountain Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.20.5 Baekdu Mountain Pharmaceutical Recent Development
11.21 Baida Pharmaceutical
11.21.1 Baida Pharmaceutical Company Details
11.21.2 Baida Pharmaceutical Business Overview and Its Total Revenue
11.21.3 Baida Pharmaceutical Antineoplastic Agents Introduction
11.21.4 Baida Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.21.5 Baida Pharmaceutical Recent Development
11.22 Jiangsu Haosen Pharmaceutical Group
11.22.1 Jiangsu Haosen Pharmaceutical Group Company Details
11.22.2 Jiangsu Haosen Pharmaceutical Group Business Overview and Its Total Revenue
11.22.3 Jiangsu Haosen Pharmaceutical Group Antineoplastic Agents Introduction
11.22.4 Jiangsu Haosen Pharmaceutical Group Revenue in Antineoplastic Agents Business (2016-2021)
11.22.5 Jiangsu Haosen Pharmaceutical Group Recent Development
11.23 Hainan Chang'an International Pharmaceutical
11.23.1 Hainan Chang'an International Pharmaceutical Company Details
11.23.2 Hainan Chang'an International Pharmaceutical Business Overview and Its Total Revenue
11.23.3 Hainan Chang'an International Pharmaceutical Antineoplastic Agents Introduction
11.23.4 Hainan Chang'an International Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.23.5 Hainan Chang'an International Pharmaceutical Recent Development
11.24 Zhejiang Kanglaite Pharmaceutical
11.24.1 Zhejiang Kanglaite Pharmaceutical Company Details
11.24.2 Zhejiang Kanglaite Pharmaceutical Business Overview and Its Total Revenue
11.24.3 Zhejiang Kanglaite Pharmaceutical Antineoplastic Agents Introduction
11.24.4 Zhejiang Kanglaite Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.24.5 Zhejiang Kanglaite Pharmaceutical Recent Development
11.25 Shandong New Era Pharmaceutical
11.25.1 Shandong New Era Pharmaceutical Company Details
11.25.2 Shandong New Era Pharmaceutical Business Overview and Its Total Revenue
11.25.3 Shandong New Era Pharmaceutical Antineoplastic Agents Introduction
11.25.4 Shandong New Era Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.25.5 Shandong New Era Pharmaceutical Recent Development
11.26 Liaoning Novino Pharmaceutical
11.26.1 Liaoning Novino Pharmaceutical Company Details
11.26.2 Liaoning Novino Pharmaceutical Business Overview and Its Total Revenue
11.26.3 Liaoning Novino Pharmaceutical Antineoplastic Agents Introduction
11.26.4 Liaoning Novino Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.26.5 Liaoning Novino Pharmaceutical Recent Development
11.27 Maanshan Fengyuan Pharmaceutical
11.27.1 Maanshan Fengyuan Pharmaceutical Company Details
11.27.2 Maanshan Fengyuan Pharmaceutical Business Overview and Its Total Revenue
11.27.3 Maanshan Fengyuan Pharmaceutical Antineoplastic Agents Introduction
11.27.4 Maanshan Fengyuan Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.27.5 Maanshan Fengyuan Pharmaceutical Recent Development
11.28 Meiluo Pharmaceutical
11.28.1 Meiluo Pharmaceutical Company Details
11.28.2 Meiluo Pharmaceutical Business Overview and Its Total Revenue
11.28.3 Meiluo Pharmaceutical Antineoplastic Agents Introduction
11.28.4 Meiluo Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.28.5 Meiluo Pharmaceutical Recent Development
11.29 Shandong Luoxin Pharmaceutical Group
11.29.1 Shandong Luoxin Pharmaceutical Group Company Details
11.29.2 Shandong Luoxin Pharmaceutical Group Business Overview and Its Total Revenue
11.29.3 Shandong Luoxin Pharmaceutical Group Antineoplastic Agents Introduction
11.29.4 Shandong Luoxin Pharmaceutical Group Revenue in Antineoplastic Agents Business (2016-2021)
11.29.5 Shandong Luoxin Pharmaceutical Group Recent Development
11.30 Zhejiang Yatai Pharmaceutical
11.30.1 Zhejiang Yatai Pharmaceutical Company Details
11.30.2 Zhejiang Yatai Pharmaceutical Business Overview and Its Total Revenue
11.30.3 Zhejiang Yatai Pharmaceutical Antineoplastic Agents Introduction
11.30.4 Zhejiang Yatai Pharmaceutical Revenue in Antineoplastic Agents Business (2016-2021)
11.30.5 Zhejiang Yatai Pharmaceutical Recent Development
11.31 Tesaro (GSK)
11.31.1 Tesaro (GSK) Company Details
11.31.2 Tesaro (GSK) Business Overview and Its Total Revenue
11.31.3 Tesaro (GSK) Antineoplastic Agents Introduction
11.31.4 Tesaro (GSK) Revenue in Antineoplastic Agents Business (2016-2021)
11.31.5 Tesaro (GSK) Recent Development
11.32 Eisai
11.32.1 Eisai Company Details
11.32.2 Eisai Business Overview and Its Total Revenue
11.32.3 Eisai Antineoplastic Agents Introduction
11.32.4 Eisai Revenue in Antineoplastic Agents Business (2016-2021)
11.32.5 Eisai Recent Development
11.33 Biogen Idec
11.33.1 Biogen Idec Company Details
11.33.2 Biogen Idec Business Overview and Its Total Revenue
11.33.3 Biogen Idec Antineoplastic Agents Introduction
11.33.4 Biogen Idec Revenue in Antineoplastic Agents Business (2016-2021)
11.33.5 Biogen Idec Recent Development
11.34 Teva
11.34.1 Teva Company Details
11.34.2 Teva Business Overview and Its Total Revenue
11.34.3 Teva Antineoplastic Agents Introduction
11.34.4 Teva Revenue in Antineoplastic Agents Business (2016-2021)
11.34.5 Teva Recent Development
11.35 AbbVie
11.35.1 AbbVie Company Details
11.35.2 AbbVie Business Overview and Its Total Revenue
11.35.3 AbbVie Antineoplastic Agents Introduction
11.35.4 AbbVie Revenue in Antineoplastic Agents Business (2016-2021)
11.35.5 AbbVie Recent Development

12 Analyst's Viewpoints/Conclusion

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

ページTOPに戻る

Table of Contents

Summary

New anti-tumor targets and corresponding new anti-tumor agents or means are: targeting cell signal transduction molecules, including protein tyrosine kinase inhibitors, farnesyltransferase (FTase) inhibitors, MAPK signaling pathway inhibitors, and cell cycle regulators.Targeting neovascularization: neovascularization inhibitors;To reduce the detachment, adhesion and basement membrane degradation of cancer cells: anti-metastasis drugs;Targeting telomerase: telomerase inhibitor;Drug resistance to tumor cells: drug resistance reversal agent;Promoting the mature differentiation of malignant cells: differentiation inducers;Specific killing of cancer cells :(antibody or toxin) directed therapy;Enhance the efficacy of radiotherapy and chemotherapy: tumor treatment sensitizers;Enhance or regulate collective immune function: biological response modulator;For oncogenes and tumor suppressor genes: gene therapy - introduction of wild-type tumor suppressor genes, suicide genes, anti-drug resistance genes and antisense oligonucleotides, tumor genetic engineering tumor bacteria.

Market Analysis and Insights: Global Antineoplastic Agents Market
In 2020, the global Antineoplastic Agents market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027.

Global Antineoplastic Agents Scope and Market Size
Antineoplastic Agents market is segmented by companies, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antineoplastic Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on market size and forecast for the period 2016-2027.
Segment by Type, the Antineoplastic Agents market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy (Biologic Therapy), Others, etc.
Segment by Application, the Antineoplastic Agents market is segmented into Plant Medicine, Hormone, Platinum Compounds, Metabolism Of Drug Resistance, Targeting Small Molecules, Drugs For Cancer, Antibiotic, Alkylating Agent, Chemoradiotherapy Protectant, etc.

Regional and Country-level Analysis
The report offers exhaustive assessment of different region-wise and country-wise Antineoplastic Agents markets such as the U.S., Canada, Germany, France, the U.K., Italy, Russia, China, Japan, South Korea, Taiwan, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Argentina, Saudi Arabia, UAE, Turkey, etc.
The report includes country-wise and region-wise market size for the period 2016-2027, by countries (regions), by Type, and by Application, as well as by players for North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Competitive Landscape and Antineoplastic Agents Market Share Analysis
Antineoplastic Agents market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2016-2021. Details included are company description, major business, company total revenue and revenue generated in Antineoplastic Agents business, the date to enter into the Antineoplastic Agents market, Antineoplastic Agents product introduction, recent developments, etc.
The major vendors include BMS, MSD, Johnson & Johnson, Pfizer, AstraZeneca, Novartis, Sanofi, Celgene, Roche, Lilly, Bayer, Abraxis, Gilead, Wto-Day Order Pharmaceutical, Sinopharm, Shandong Lvye Pharmaceutical, CTTQ, Jiangsu Hengrui Pharmaceutical, Qilu Pharmaceutical, Baekdu Mountain Pharmaceutical, etc.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（薬学的薬物）の最新刊レポート

皮膚科治療薬市場レポート：2024-2034

QYResearch社のその他分野での最新刊レポート

本レポートと同じKEY WORD（antineoplastic agents）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

QYResearch社はどのような調査会社ですか?

QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

世界の抗悪性腫瘍剤の主要動向と2027年までの機会

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（薬学的薬物）の最新刊レポート

QYResearch社のその他分野での最新刊レポート

本レポートと同じKEY WORD（antineoplastic agents）の最新刊レポート

よくあるご質問

QYResearch社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?